|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-3-31
|
|
pubmed:abstractText |
Not all patients with complement deposition of the heart have developed hemodynamic instability at the time of diagnosis, suggesting that immunoprotective mechanisms reside within grafts. We hypothesized that decay-accelerating factor (DAF) could provide a first-line defense against complement injury, thus explaining the discrepancy in hemodynamics. Thus, we examined the role of DAF in the clinical presentation of antibody-mediated cardiac allograft rejection.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD55,
http://linkedlifedata.com/resource/pubmed/chemical/Coloring Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Complement C3d,
http://linkedlifedata.com/resource/pubmed/chemical/Complement C4b,
http://linkedlifedata.com/resource/pubmed/chemical/Eosine Yellowish-(YS),
http://linkedlifedata.com/resource/pubmed/chemical/Fluorescent Dyes,
http://linkedlifedata.com/resource/pubmed/chemical/Hematoxylin,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/complement C4d
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1557-3117
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
357-61
|
|
pubmed:meshHeading |
pubmed-meshheading:18374870-Adolescent,
pubmed-meshheading:18374870-Adult,
pubmed-meshheading:18374870-Aged,
pubmed-meshheading:18374870-Antibodies,
pubmed-meshheading:18374870-Antigens, CD55,
pubmed-meshheading:18374870-Coloring Agents,
pubmed-meshheading:18374870-Complement C3d,
pubmed-meshheading:18374870-Complement C4b,
pubmed-meshheading:18374870-Endocardium,
pubmed-meshheading:18374870-Eosine Yellowish-(YS),
pubmed-meshheading:18374870-Female,
pubmed-meshheading:18374870-Fluorescent Antibody Technique,
pubmed-meshheading:18374870-Fluorescent Dyes,
pubmed-meshheading:18374870-Graft Rejection,
pubmed-meshheading:18374870-Heart,
pubmed-meshheading:18374870-Heart Transplantation,
pubmed-meshheading:18374870-Hematoxylin,
pubmed-meshheading:18374870-Humans,
pubmed-meshheading:18374870-Male,
pubmed-meshheading:18374870-Middle Aged,
pubmed-meshheading:18374870-Myocardium,
pubmed-meshheading:18374870-Peptide Fragments,
pubmed-meshheading:18374870-Pilot Projects,
pubmed-meshheading:18374870-Postoperative Period,
pubmed-meshheading:18374870-Staining and Labeling,
pubmed-meshheading:18374870-Transplantation, Homologous
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection.
|
|
pubmed:affiliation |
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. gonzalg@ccf.org
|
|
pubmed:publicationType |
Journal Article
|
